Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
PANACEA LIFE SCIENCES HOLDINGS, INC. incurred convertible notes of $385,000 Senior Convertible Note with an institutional investor maturing March 3, 2022 (dated); repayment terms include a Note Payoff Agreement dated February 9, 2023.
- Instrument
- convertible notes
- Principal
- $385,000 Senior Convertible Note
- Counterparty
- an institutional investor
- Maturity
- March 3, 2022 (dated); repayment terms include a Note Payoff Agreement dated February 9, 2023
- Event
- incurrence
Exact text from the filing
the Investor exchanged 350 shares of the Company’s Series A Preferred Stock, par value $0.0001, for a Senior Convertible Note dated March 3, 2022 in the principal amount of $385,000, as amended (the “Note”). The parties have agreed that the Company will repay the Note in full pursuant to the terms of a Note Payoff Agreement dated February 9, 2023
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
PANACEA LIFE SCIENCES HOLDINGS, INC. entered into Share Exchange Agreement with institutional investor valued at Senior Convertible Note dated March 3, 2022 in the principal amount of $385,000, as amended (effective 2022-03-03).
- Action
- entry
- Agreement
- notes offering
- Counterparty
- institutional investor
- Value
- Senior Convertible Note dated March 3, 2022 in the principal amount of $385,000, as amended
- Effective
- 2022-03-03
Exact text from the filing
On March 3, 2022, Panacea Life Sciences Holdings, Inc. (the “Company”) entered into a Share Exchange Agreement with an institutional investor (the “Investor”) pursuant to which the Investor exchanged 350 shares of the Company’s Series A Preferred Stock, par value $0.0001, for a Senior Convertible Note dated March 3, 2022 in the principal amount of $385,000, as amended (the “Note”).
View on SEC.gov